Epstein-Barr virus molecular epidemiology and variants identification in head and neck squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
DNA, Viral
/ analysis
Epstein-Barr Virus Infections
/ complications
Epstein-Barr Virus Nuclear Antigens
/ genetics
Female
Follow-Up Studies
Genetic Variation
Genotype
Head and Neck Neoplasms
/ epidemiology
Herpesvirus 4, Human
/ classification
Humans
Male
Middle Aged
Molecular Epidemiology
Prognosis
Squamous Cell Carcinoma of Head and Neck
/ epidemiology
Viral Proteins
/ genetics
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
19
11
2019
medline:
31
8
2021
entrez:
19
11
2019
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV) is known as one of the most widespread oncogenic viruses. Head and neck squamous cell carcinoma (HNSCC) is triggered by various risk factors. The aim of the present study was to determine the EBV infection rate, genotyping and variants frequency in HNSCC patients. In this cross-sectional study, 156 patients with HNSCC were enrolled. Formalin fixed paraffin embedded (FFPE) tissue samples were selected from hospitals affiliated to Iran University of Medical Sciences, Tehran, Iran. The EBV EBNA-3C, EBNA-1 and LMP-1 genes were amplified by PCR and then analyzed and confirmed by nucleotide sequencing. CLC work bench 5, MEGA6 and SPSS v.21 software were used for analysis the raw data. The mean age ± SD (years) of the all patients (n = 156) was 60.5 ± 12.6, in which of 121(77.6%) males it was 60.7 ± 11.9 and of 35 (22.4%) females it was 59.7 ± 14.9. Totally, 20 samples (12.8%) were found to be infected with EBV genome. The EBV genotypes 1 and 2 were calculated 90% (18/20) and 10% (2/20), respectively. vLMP-1 found in 40% (4/10) of all LMP-1 tested samples. Furthermore, the EBNA-1 predominant variants were P-ala followed by P-thr and also there were three P-ala-v2 sub variants. Statistics could not find any significant associations although there were some potentials. By our preliminary study in Iran, it revealed that EBV-1 is the predominant Epstein-Barr virus genotype in head and neck squamous cell carcinoma patients. vLMP-1 isolates showed lower survival rate than others. EBNA-1 variants had no significant association with any specific disease complication.
Identifiants
pubmed: 31738221
doi: 10.1097/CEJ.0000000000000554
pii: 00008469-202011000-00008
doi:
Substances chimiques
DNA, Viral
0
Epstein-Barr Virus Nuclear Antigens
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-530Références
Ai J, Xie Z, Liu C, Huang Z, Xu J. Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children. Virol J. 2012; 9:13
Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology. 2001; 282:278–287
Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005; 130:662–670
Chan KA, Hung EC, Woo JK, Chan PK, Leung SF, Lai FP, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer. 2013; 119:1838–1844
Chang KL, Chen YY, Chen WG, Hayashi K, Bacchi C, Bacchi M, Weiss LM. EBNA-1 gene sequences in Brazilian and American patients with Hodgkin’s disease. Blood. 1999; 94:244–250
Cheung ST, Lo KW, Leung SF, Chan WY, Choi PH, Johnson PJ, et al. Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumors in hong kong. Int J Cancer. 1996; 66:711–712
Dardari R, Khyatti M, Cordeiro P, Odda M, ElGueddari B, Hassar M, Menezes J. High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein-Barr virus -associated nasopharyngeal carcinoma in Moroccan patients. Int J Cancer. 2006; 118:1977–1983
Deng Z, Uehara T, Maeda H, Hasegawa M, Matayoshi S, Kiyuna A, et al. Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers. Plos One. 2014; 9:e113702
Do NV, Ingemar E, Phi PT, Jenny A, Chinh TT, Zeng Y, Hu L. A major EBNA1 variant from Asian EBV isolates shows enhanced transcriptional activity compared to prototype B95.8. Virus Res. 2008; 132:15–24
Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology. 1999; 261:79–95
Fassone L, Bhatia K, Gutierrez M, Capello D, Gloghini A, Dolcetti R, et al. Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. Leukemia. 2000; 14:271–277
Gaal K, Weiss LM, Chen WG, Chen YY, Arber DA. Epstein-Barr virus nuclear antigen (EBNA)-1 carboxy-terminal and EBNA-4 sequence polymorphisms in nasal natural killer/T-cell lymphoma in the united states. Lab Invest. 2002; 82:957–962
Goldenberg D, Benoit NE, Begum S, Westra WH, Cohen Y, Koch WM, et al. Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction. Laryngoscope. 2004; 114:1027–1031
Greiner TC, Abou-Elella AA, Smir BN, Orazi A, Hinrichs S, Anderson J, et al. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations. Leuk Lymphoma. 2000; 38:563–576
Guti M, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, et al. Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. J Gen Virol. 1997; 78:1663–1670
Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. J Virol. 1999; 73:965–975
Hadhri-Guiga B, Khabir AM, Mokdad-Gargouri R, Ghorbel AM, Drira M, Daoud J, et al. Various 30 and 69 bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res. 2006; 115:24–30
Haque S, Karivedu V, Riaz MK, Choi D, Roof L, Hassan SZ, et al. High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma. Oral Oncol. 2019; 88:9–15
Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18:541–550
Higa M, Kinjo T, Kamiyama K, Iwamasa T, Hamada T, Iyama K. Epstein-Barr virus (EBV) subtype in EBV related oral squamous cell carcinoma in Okinawa, a subtropical island in southern Japan, compared with Kitakyushu and Kumamoto in mainland Japan. J Clin Pathol. 2002; 55:414–423
Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 1995; 10:549–560
IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Epstein-Barr Virus and Kaposi’s Sarcoma Herpesvirus/Human Herpesvirus 8. 1997, Lyon (FR): International Agency for Research on Cancer. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 70.) Available at: https://www.ncbi.nlm.nih.gov/books/NBK385507/
Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995; 103:308–315
Jalouli J, Jalouli MM, Sapkota D, Ibrahim SO, Larsson PA, Sand L. Human papilloma virus, herpes simplex virus and Epstein Barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res. 2012; 32:571–580
Jeon YK, Lee BY, Kim JE, Lee SS, Kim CW. Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck. 2004; 26:573–583
Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus–associated lymphoproliferative disorders and malignant lymphomas. Blood. 1996; 88:242–251
Kis A, Fehér E, Gáll T, Tar I, Boda R, Tóth ED, et al. Epstein-Barr virus prevalence in oral squamous cell cancer and in potentially malignant oral disorders in an eastern Hungarian population. Eur J Oral Sci. 2009; 117:536–540
Lankarani KB, Afshari R. Alcohol consumption in iran. Lancet. 2014; 384:1927–1928
Lin Z, Khong B, Kwok S, Cao H, West RB, Le QT, Kong CS. Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic southern Chinese patients. Head Neck. 2014; 36:709–714
Lo EJ, Bell D, Woo JS, Li G, Hanna EY, El-Naggar AK, Sturgis EM. Human papillomavirus and WHO type I nasopharyngeal carcinoma. Laryngoscope. 2010; 120:1990–1997
Lorenzetti MA, Altcheh J, Moroni S, Moscatelli G, Chabay PA, Preciado M V. EBNA1 sequences in Argentinean pediatric acute and latent Epstein-Barr virus infection reflect circulation of novel South American variants. J Med Virol. 2010; 82:1730–1738
MacKenzie J, Gray D, Pinto-Paes R, Barrezueta LF, Armstrong AA, Alexander FA, et al. Analysis of Epstein-Barr virus (EBV) nuclear antigen 1 subtypes in EBV-associated lymphomas from brazil and the united kingdom. J Gen Virol. 1999; 80Pt 102741–2745
Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008; 83:489–501
Middeldorp JM. Epstein-Barr virus-specific humoral immune responses in health and disease. Curr Top Microbiol Immunol. 2015; 391:289–323
Mitchell T, Sugden B. Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol. 1995; 69:2968–2976
Niya MHK, Tameshkel FS, Panahi M, Salim FB, Monavari SHR, Keyvani H. Human papillomavirus investigation in head and neck squamous cell carcinoma: initial report from the low risk HPV types associations. Asian Pac J Cancer Prev: APJCP. 2017; 18:2573
Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, et al. Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies. Oncology. 2015; 89:125–136
Rautava J, Kuuskoski J, Syrjänen K, Grenman R, Syrjänen S. HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. J Clin Virol. 2012; 53:116–120
Sandvej K, Zhou XG, Hamilton-Dutoit S. EBNA-1 sequence variation in danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. J Pathol. 2000; 191:127–131
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30
Singhi AD, Califano J, Westra WH. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck. 2012; 34:213–218
Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. Plos One. 2010; 5:e10094
Snudden DK, Smith PR, Lai D, Ng MH, Griffin BE. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene. 1995; 10:1545–1552
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus -induced disease. Annu Rev Immunol. 2015; 33:787–821
Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002; 99:10084–10089
Tuna M, Amos CI, Mills GB. Genome-wide analysis of head and neck squamous cell carcinomas reveals HPV, TP53, smoking and alcohol-related allele-based acquired uniparental disomy genomic alterations. Neoplasia. 2019; 21:197–205
Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol. 2015; 235:312–322
Wang Y, Liu X, Xing X, Cui Y, Zhao C, Luo B. Variations of Epstein-Barr virus nuclear antigen 1 gene in gastric carcinomas and nasopharyngeal carcinomas from northern china. Virus Res. 2010; 147:258–264
Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365:2041–2054
Wu SJ, Lay JD, Chen CL, Chen JY, Liu MY, Su IJ. Genomic analysis of Epstein-Barr virus in nasal and peripheral T-cell lymphoma: a comparison with nasopharyngeal carcinoma in an endemic area. J Med Virol. 1996; 50:314–321
Zhang YQ, MacLennan R, Berry G. Mortality of Chinese in new south wales, 1969-1978. Int J Epidemiol. 1984; 13:188–192
Zheng Y, Xia P, Zheng HC, Takahashi H, Masuda S, Takano Y. The screening of viral risk factors in tongue and pharyngolaryngeal squamous carcinoma. Anticancer Res. 2010; 30:1233–1238